Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pantec Biosolutions

This article was originally published in The Gray Sheet

Executive Summary

The laser-based drug delivery technology developer closes a $19 million investment round, led by StemCell Holding AG. Announced July 20, the funding will support ongoing clinical trials of Pantec's P.L.E.A.S.E. (Painless Laser Epidermal System) technology for delivering in vitro fertilization hormone therapy. "This financing will allow us to move ahead with the clinical development of the [IVF] platform and visualize our goal of reaching market approval in Europe," said CEO Christof Boehler. Headquartered in Liechtenstein, privately held Pantec's technology uses a handheld laser to create "controlled aqueous micropores in the epidermis" for transdermal delivery of high molecular weight drugs, the company explains. Pantec values the IVF hormone therapy market at $1.5 billion to $2 billion

You may also be interested in...

Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts